What Is The Influence Of Tumor Removal On The Serum Level Of Carbohydrate's Antibody?

Main Category: Cancer / Oncology
Also Included In: Immune System / Vaccines;  GastroIntestinal / Gastroenterology
Article Date: 08 Oct 2008 - 10:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Cancer immune surveillance is considered to be important in the anti-tumor protection of the host. The growing tumor escapes the immune control under the immunosuppressive conditions. The surgical removal of the tumor may reverse the immunosuppression. The TF antigen and Tn belong to tumor-associated carbohydrate antigens (TACA). TF antigen is implicated in the metastatic spread due to the adhesion of cancer cells to the endothelium. However, the dynamic changes of the level of TF and Tn-antibodies in the serum of patients with cancer and its association with survival have been insufficiently studied.

A research article published on July 21, 2008 in the World Journal of Gastroenterology addresses this question. The research team led by Dr. Kurtenkov from National Institute for Health Development (Tallinn, Estonia) have undertaken a long-term follow-up of cancer patients to determine changes in the postoperative level of TF- and Tn antibodies, as well as to elucidate the association of this level with the progression of cancer, and survival. The level of antibodies in serum was determined by the ELISA using synthetic polyacrylamide (PAA) glycoconjugates.

They found that in gastrointestinal cancer, the TF antibody level was found to have elevated significantly after the removal of G3 tumors as compared with the preoperative level (u = 278.5, P < 0.05). After surgery, the TF and Tn antibody level was elevated in the majority of gastric cancer patients (sign test, 20 vs 8, P < 0.05, and 21 vs 8, P < 0.05, respectively). In gastrointestinal cancer, the elevated postoperative level of TF, Tn and Gal antibodies was noted in most patients with G3 tumors (sign test, 22 vs 5, P < 0.01; 19 vs 6, P < 0.05; 24 vs 8, P < 0.01, respectively), but the elevation was not significant in patients with G1 + G2 resected tumors. The postoperative follow-up showed that the percentage of patients with G3 resected tumors of the digestive tract, who had a mean level of anti-TF IgG above the cutoff value (1.53), was significantly higher than that of patients with G1 + G2 resected tumors (chi2 = 3.89, all patients; chi2 = 5.34, patients without regional lymph node metastases; P < 0.05). The percentage of patients with a tumor in stage I, whose mean anti-TF IgG level remained above the cut-off value (1.26), was significantly higher than that of patients with the cancer in stages II I-IV (chi2 = 4.71, gastric cancer; chi2 = 4.11, gastrointestinal cancer; P < 0.05). The correlation was observed to exist between the level of anti-TF IgG and the count of lymphocytes (r = 0.517, P < 0.01), as well as between the level of anti-Tn IgG and that of serum CA 19-9 (r = 0.481, P < 0.05). No positive delayed-type hypersensitivity reaction in skin test challenges with TF-PAA in any of the fifteen patients, including those with a high level of anti-TF IgG, was observed.

Their result indicated that the surgical operation raises the level of anti-carbohydrate IgG in most patients, especially in those with the G3 tumor of the gastrointestinal tract. The stage and morphology-dependent immuneosuppression affects the TF-antibody response and may be one of the reasons for unresponsiveness to the immunization with TF-antigens.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

Reference: Smorodin EP, Kurtenkov O, Sergeyev BL, Kodar K, Chuzmarov VI, Afanasyev VP. Postoperative change of anti-TF and Tn IgG level: The follow-up study of gastrointestinal cancer patients. World J Gastroenterol 2008;14(27): 4352-4358 http://www.wjgnet.com/1007-9327/14/4352.asp

Correspondence to: Eugeniy Smorodin, Ph.D, Department of Oncology & Immunology, National Institute for Health Development, Hiiu 42, Tallinn 11619, Estonia.

About World Journal of Gastroenterology

World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H pylori infection and provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2003-2000 IF: 3.318, 2.532, 1.445 and 0.993. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th day of every month. WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the name of China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.

About The WJG Press

The WJG Press mainly publishes World Journal of Gastroenterology.

Source: Lai-Fu Li
World Journal of Gastroenterology